


CPTH2 hydrochloride

Cat. No.:	HY-W013274A
CAS No.:	2108899-91-6
Molecular Formula:	C ₁₄ H ₁₅ Cl ₂ N ₃ S
Molecular Weight:	328.26
Target:	Histone Acetyltransferase; Apoptosis
Pathway:	Epigenetics; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CPTH2 hydrochloride is a potent histone acetyltransferase (HAT) inhibitor. CPTH2 hydrochloride selectively inhibits the acetylation of histone H3 by Gcn5. CPTH2 hydrochloride induces apoptosis and decreases the invasiveness of a clear cell renal carcinoma (ccRCC) cell line through the inhibition of acetyltransferase p300 (KAT3B) ^{[1][2]} .												
IC₅₀ & Target	GCN5												
In Vitro	<p>CPTH2 (100 μM; 12, 24, 48 hours) hydrochloride causes a decrease in cell proliferation after as early as 12 h with a further significant reduction after 48 h stimulation^[1].</p> <p>CPTH2 (100 μM; 12 or 48 hours) hydrochloride causes a comparable drop of the activity in both cell lines^[1].</p> <p>CPTH2 (100 μM; 48 hours) hydrochloride produces a drastic increase in apoptotic/dead cell population after 48 h^[1].</p> <p>CPTH2 (100 μM; 12, 24, 48 hours) hydrochloride shows a reduced acetylation of both global AcH3 histone and H3AcK18^[1].</p> <p>CPTH2 (100 μM; 24, 48 hours) hydrochloride is capable to counteract invasion and migration of ccRCC-786-O cells in culture^[1].</p> <p>CPTH2 (0.2, 0.5, 1 mM) hydrochloride inhibits the growth of a GCN5 deleted strain and a single catalytic mutant E173H^[2].</p> <p>CPTH2 (0.6, 0.8 mM; for 24 hours) hydrochloride inhibits histone H3 acetylation in yeast cell cultures^[2].</p> <p>CPTH2 hydrochloride inhibits the Gcn5p dependent functional network^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Papillary thyroid (K1) and clear cell Renal Cell Carcinoma (ccRCC-786-O) cell lines</td> </tr> <tr> <td>Concentration:</td> <td>100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>12, 24, 48 hours</td> </tr> <tr> <td>Result:</td> <td>Caused a decrease in cell proliferation after as early as 12 h with a further significant reduction after 48 h stimulation.</td> </tr> </table> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>K1 and ccRCC-786-O cell lines</td> </tr> <tr> <td>Concentration:</td> <td>100 μM</td> </tr> </table>	Cell Line:	Papillary thyroid (K1) and clear cell Renal Cell Carcinoma (ccRCC-786-O) cell lines	Concentration:	100 μM	Incubation Time:	12, 24, 48 hours	Result:	Caused a decrease in cell proliferation after as early as 12 h with a further significant reduction after 48 h stimulation.	Cell Line:	K1 and ccRCC-786-O cell lines	Concentration:	100 μM
Cell Line:	Papillary thyroid (K1) and clear cell Renal Cell Carcinoma (ccRCC-786-O) cell lines												
Concentration:	100 μM												
Incubation Time:	12, 24, 48 hours												
Result:	Caused a decrease in cell proliferation after as early as 12 h with a further significant reduction after 48 h stimulation.												
Cell Line:	K1 and ccRCC-786-O cell lines												
Concentration:	100 μM												

Incubation Time:	24 hours (K1 cell) and 48 hours (ccRCC-786-O cell)
Result:	Caused a comparable drop of the activity in both cell lines.
Apoptosis Analysis ^[1]	
Cell Line:	ccRCC-786-O cells
Concentration:	100 μ M
Incubation Time:	48 hours
Result:	Produced a drastic increase in apoptotic/dead cell population after 48 h.
Western Blot Analysis ^[1]	
Cell Line:	ccRCC-786-O cells
Concentration:	100 μ M
Incubation Time:	12, 24, 48 hours
Result:	Showed a reduced acetylation of both global AcH3 histone and H3AcK18.

REFERENCES

[1]. Cocco E, et al. KAT3B-p300 and H3AcK18/H3AcK14 levels are prognostic markers for kidney ccRCC tumor aggressiveness and target of KAT inhibitor CPTH2. Clin Epigenetics. 2018 Apr 4;10:44.

[2]. Chimenti F, et al. A novel histone acetyltransferase inhibitor modulating Gcn5 network: cyclopentylidene-[4-(4'-chlorophenyl)thiazol-2-yl]hydrazone. J Med Chem. 2009 Jan 22;52(2):530-6.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA